Merck & Co., known as MSD outside the U.S. and Canada, announced a research collaboration with Isomorphic Labs on 19 November 2026. The partnership will utilize Isomorphic Labs' proprietary IsoDDE AI engine to discover small-molecule therapeutic candidates for a strategically significant oncology target.
MSD announced an early-stage research collaboration with privately held Isomorphic Labs to use its AI engine (IsoDDE) for small-molecule discovery against a single oncology target. MSD controls preclinical/clinical development, manufacturing and commercialization, but the announcement discloses no financial terms, upfront payment amount or milestone figures. For a company of Merck's size, a single unquantified discovery deal is routine and unlikely to move the share price.
- • Research collaboration with Isomorphic Labs on a strategically important oncology target announced 19 November 2026
- • No financial terms or payment amounts were disclosed
- • Any product candidate would still need to clear preclinical and clinical development with no guarantee of regulatory approval